JP2024540402A5 - - Google Patents

Info

Publication number
JP2024540402A5
JP2024540402A5 JP2024527084A JP2024527084A JP2024540402A5 JP 2024540402 A5 JP2024540402 A5 JP 2024540402A5 JP 2024527084 A JP2024527084 A JP 2024527084A JP 2024527084 A JP2024527084 A JP 2024527084A JP 2024540402 A5 JP2024540402 A5 JP 2024540402A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
structural formula
immune complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/048735 external-priority patent/WO2023081230A1/en
Publication of JP2024540402A publication Critical patent/JP2024540402A/ja
Publication of JP2024540402A5 publication Critical patent/JP2024540402A5/ja
Pending legal-status Critical Current

Links

JP2024527084A 2021-11-03 2022-11-02 新規オーリスタチン類似体およびその免疫複合体 Pending JP2024540402A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US63/275,177 2021-11-03
US202163295476P 2021-12-30 2021-12-30
US63/295,476 2021-12-30
PCT/US2022/048735 WO2023081230A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Publications (2)

Publication Number Publication Date
JP2024540402A JP2024540402A (ja) 2024-10-31
JP2024540402A5 true JP2024540402A5 (https=) 2025-11-12

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527084A Pending JP2024540402A (ja) 2021-11-03 2022-11-02 新規オーリスタチン類似体およびその免疫複合体

Country Status (9)

Country Link
EP (1) EP4426714A4 (https=)
JP (1) JP2024540402A (https=)
KR (1) KR20240110584A (https=)
AU (1) AU2022380491A1 (https=)
CA (1) CA3236944A1 (https=)
IL (1) IL312533A (https=)
MX (1) MX2024005342A (https=)
TW (1) TW202334176A (https=)
WO (1) WO2023081230A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067221A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 奥瑞他汀衍生物及其抗体药物偶联物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Similar Documents

Publication Publication Date Title
KR102486055B1 (ko) 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
JP2025066807A (ja) 生体直交型組成物
JP2021527040A5 (https=)
JP2022087255A (ja) キャリア結合剤組成物およびそれを作製および使用する方法
JP2025509286A5 (https=)
JP2021121590A5 (https=)
TW202010498A (zh) 喜樹鹼肽結合物
JP7465347B2 (ja) 抗c-Met抗体薬物複合体
JP2022512643A5 (https=)
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
JP2009501800A5 (https=)
JP2017506234A5 (https=)
TWI558399B (zh) 癌症之組合療法
JP2022546110A5 (https=)
JP2024540402A5 (https=)
JP2023529640A (ja) 治療用コンジュゲート
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
NL2020121B1 (en) Platinum-based functional moieties for preparing cell targeting conjugates
JP2023512227A5 (https=)
JP2025500404A5 (https=)
TW201919711A (zh) 預防免疫結合物中之甲硫胺酸氧化之方法
JP2023512206A5 (https=)
JPH07223969A (ja) チオエーテル結合体の製造法
JP2023512228A5 (https=)
JP2023546293A5 (https=)